Literature DB >> 18678563

Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo.

Neng-Wei Hu1, Imelda M Smith, Dominic M Walsh, Michael J Rowan.   

Abstract

Long before the onset of clinical Alzheimer's disease non-fibrillar, soluble assembly states of amyloid-beta (Abeta) peptides are believed to cause cognitive problems by disrupting synaptic function in the absence of significant neurodegeneration. Since many of the risk factors for Alzheimer's disease are vascular, impairment of cerebral blood flow by soluble Abeta has been proposed to be critical in triggering these early changes. However, it is not known if soluble Abeta can affect cerebrovascular function at the concentrations required to cause inhibition of synaptic plasticity mechanisms believed to underlie the early cognitive deficits of Alzheimer's disease. Here we developed a new method to simultaneously assess the ability of soluble Abeta to impair plasticity at synapses and to affect resting and activity-dependent local blood flow in the rat hippocampus in vivo. Intracerebroventricular injection of soluble synthetic Abeta(40) dimers rapidly inhibited plasticity of excitatory synaptic transmission at doses (10-42 pmol) comparable to natural Abeta, but failed to affect vascular function measured using laser-Doppler flowmetry (LDF). Like wild-type Abeta(40), the more vasculotropic Abeta produced by people with familial hemorrhagic stroke of the Dutch type (Abeta(40)E22Q), impaired hippocampal plasticity without causing a significant change in local blood flow. Furthermore, neither resting nor activation-evoked hippocampal perfusion was affected by soluble Abeta(42), even at a concentration that markedly (25%) reduced baseline synaptic transmission. These findings demonstrate that the putative synaptotoxic soluble Abeta species of early Alzheimer's disease cause synaptic dysfunction in the absence of detectible changes in local blood flow. This strongly indicates that early cognitive deficits can be caused by soluble Abeta independently of deleterious effects on cerebrovascular dynamics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18678563     DOI: 10.1093/brain/awn174

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  33 in total

1.  Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.

Authors:  Karienn S Montgomery; George Edwards; Yona Levites; Ashok Kumar; Catherine E Myers; Mark A Gluck; Barry Setlow; Jennifer L Bizon
Journal:  Hippocampus       Date:  2015-10-19       Impact factor: 3.899

2.  Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.

Authors:  Marc Aurel Busche; Xiaowei Chen; Horst A Henning; Julia Reichwald; Matthias Staufenbiel; Bert Sakmann; Arthur Konnerth
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-16       Impact factor: 11.205

Review 3.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 4.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

Review 5.  Cognitive reserve and Alzheimer's disease.

Authors:  Wei Xu; Jin-Tai Yu; Meng-Shan Tan; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

6.  Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes.

Authors:  Diego Iacono; Susan M Resnick; Richard O'Brien; Alan B Zonderman; Yang An; Olga Pletnikova; Gay Rudow; Barbara Crain; Juan C Troncoso
Journal:  J Neuropathol Exp Neurol       Date:  2014-04       Impact factor: 3.685

7.  Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.

Authors:  Igor Klyubin; Tomas Ondrejcak; Jennifer Hayes; William K Cullen; Alexandra J Mably; Dominic M Walsh; Michael J Rowan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-12-02       Impact factor: 6.237

Review 8.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

9.  New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF.

Authors:  Ting Yang; Soyon Hong; Tiernan O'Malley; Reisa A Sperling; Dominic M Walsh; Dennis J Selkoe
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

10.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.